Get the Stockscreener App
12.54
0.97%
0.12
Mediwound Ltd stock is traded at $12.54, with a volume of 92,646.
It is up +0.97% in the last 24 hours and down -9.39% over the past month.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
See More
Previous Close:
$12.42
Open:
$12.42
24h Volume:
92,646
Relative Volume:
1.37
Market Cap:
$161.89M
Revenue:
$14.48M
Net Income/Loss:
$-26.11M
P/E Ratio:
-5.5509
EPS:
-2.2591
Net Cash Flow:
$-23.86M
1W Performance:
-7.25%
1M Performance:
-9.39%
6M Performance:
-29.43%
1Y Performance:
-29.94%
1-Day Range:
$12.42
$13.15
1-Week Range:
$12.42
$13.63
52-Week Range:
$12.42
$20.03
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDWD
Mediwound Ltd
|
12.54 | 161.89M | 14.48M | -26.11M | -23.86M | -2.2591 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-02-25 | Initiated | Alliance Global Partners | Buy |
| Feb-28-25 | Initiated | Craig Hallum | Buy |
| Jul-16-24 | Reiterated | Maxim Group | Buy |
| Dec-22-22 | Initiated | Maxim Group | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Sep-23-20 | Initiated | BTIG Research | Buy |
| Nov-28-16 | Initiated | Aegis Capital | Buy |
| Aug-17-16 | Initiated | Wells Fargo | Outperform |
| Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
Mediwound Ltd Stock (MDWD) Latest News
Avoiding Lag: Real-Time Signals in (MDWD) Movement - Stock Traders Daily
Weekly Recap: DoD funding for NexoBrid and VALUE Phase III reassessment - TradingView
TD Cowen reiterates MediWound stock rating ahead of trial data By Investing.com - Investing.com Canada
TD Cowen reiterates MediWound stock rating ahead of trial data By Investing.com - Investing.com Australia
TD Cowen reiterates MediWound stock rating ahead of trial data - Investing.com
MediWound Ltd. (MDWD) Stock Price, News, Quote & History - Yahoo! Finance Canada
MediWound Ltd. Receives Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid - marketscreener.com
MDWD Looks 11.4% Overvalued on GF Value™ - GuruFocus
Understanding the Setup: (MDWD) and Scalable Risk - Stock Traders Daily
Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) - benzinga.com
MediWound receives $3.3M from DoD for NexoBrid development By Investing.com - Investing.com Canada
MediWound receives $3.3M from DoD for NexoBrid development - Investing.com
MediWound receives $3.3M from DoD for NexoBrid development By Investing.com - Investing.com Nigeria
MediWound Awarded Additional $3.3 Million from U.S. - GlobeNewswire
MediWound Awarded Additional $3.3 Million from U.S. - GlobeNewswire
A $21.8M program is developing burn care that can stay at room temperature - Stock Titan
MediWound Awarded Additional $3.3 Million from U.S. - globenewswire.com
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid® - Yahoo Finance
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification - Yahoo Finance
Reviewers found no safety concerns in MediWound's wound trial. - stocktitan.net
(MDWD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Director of MediWound (NASDAQ: MDWD) trades shares via spouse - stocktitan.net
An FDA-approved burn treatment company’s CEO will join a New York fireside chat. - stocktitan.net
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Precision Trading with Mediwound Ltd. (MDWD) Risk Zones - Stock Traders Daily
Hungarian fund owns double-digit MediWound (MDWD) stake - stocktitan.net
MediWound (NASDAQ: MDWD) seller Hess plans $50K, 3,958-share sale - stocktitan.net
New Research Estimates a $4 Billion Market by 2028, and MediWound Thinks It May Have a Solution (Nasdaq - Benzinga
MediWound (MDWD) Q2 2026 Earnings Call Transcript - AOL.ca
MediWound (MDWD) Q2 2026 Earnings Call Transcript - AOL.com
MediWound (MDWD) Q2 2026 Earnings Call Transcript - The Globe and Mail
MediWound (MDWD) Q2 2026 Results: The Available Earnings Metric Delivers a Beat in the Current Update; Closing Reaction: The Stock Records a 1.87% Increase in the Current UpdateRevenue Per Share - vinanet.vn
MediWound (MDWD) Q2 2026 Results: The Available Earnings Metric Delivers a Beat in the Current Update; Closing Reaction: The Stock Records a 1.87% Increase in the Current UpdateEarnings Forecast Report - siam.in
MediWound (MDWD) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Share-Price Check: Shares Move 1.87% Up on the DayNegative Surprise Momentum - dars.gov.et
MediWound (MDWD) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Share-Price Check: Shares Move 1.87% Up on the DayProfit Growth Outlook - vinanet.vn
What is HC Wainwright's Forecast for MediWound Q3 Earnings? - MarketBeat
MediWound (MDWD) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Share-Price Check: Shares Move 1.87% Up on the DayCost Structure Review - dars.gov.et
Weekly Recap: Reaffirmed 2026 guidance and EscharEx Phase III enrollment - TradingView
MDWD Looks 30.8% Overvalued on GF Value™ - GuruFocus
MDWD Looks 30.8% Overvalued on GF Value™ - GuruFocus
Mediwound Ltd (MDWD) Stock News Today - TradingKey
MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - Moomoo
MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - webull.com
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Wall Street Zen Downgrades MediWound (NASDAQ:MDWD) to Strong Sell - MarketBeat
MediWound (MDWD) Stock Faces Cash Burn As Revenue Slips - simplywall.st
MediWound Q2 2026 Earnings Call: Complete Transcript - Sahm
A Quick Look at Today's Ratings for MediWound(MDWD.US), With a Forecast Between $22 to $36 - Moomoo
Mediwound Ltd Stock (MDWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mediwound Ltd Stock (MDWD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rubinstein Samuel | Director |
Sep 01 '26 |
Sale |
12.72 |
525 |
6,678 |
0 |
| Hess Shmuel | COO & Chief Commercial Officer |
Aug 27 '26 |
Sale |
12.92 |
3,958 |
51,149 |
0 |
| Shmulik Hess | Officer |
Aug 27 '26 |
Proposed Sale |
12.70 |
3,958 |
50,267 |
0 |
| Hess Shmuel | COO & Chief Commercial Officer |
Aug 26 '26 |
Sale |
13.00 |
1,865 |
24,245 |
0 |
| SHAMIR NACHUM | Director |
Jun 03 '26 |
Buy |
14.00 |
6,000 |
83,996 |
55,815 |
| Fox David Morton | Director |
Jun 01 '26 |
Buy |
14.11 |
3,537 |
49,901 |
22,283 |
| Rubinstein Samuel | Director |
May 29 '26 |
Buy |
14.33 |
150 |
2,150 |
2,993 |
| Hess Shmuel | Officer |
Dec 02 '25 |
Proposed Sale |
17.21 |
3,693 |
63,557 |
0 |
1.64%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):